Enzymatic extract fromEcklonia cava: Acute and subchronic oral toxicity and genotoxicity studies

    loading  Checking for direct PDF access through Ovid


Ecklonia cava (EC) is known to have antioxidant, anti-inflammatory, antidiabetic, and anticancer properties. Despite its wide use and beneficial properties, comprehensive toxicological information regarding EC extract is currently limited. Therefore, the purpose of this study was to investigate acute toxicity, subchronic toxicity, and genotoxicity of enzymatic EC extract according to test guidelines published by Organization for Economic Cooperation and Development. The acute oral LD50 values of this EC extract administered to rats and dogs were estimated to be more than 3000 mg/kg BW. In an oral 13-week toxicity study, changes in body weights of rats exposed to the EC extract up to 3000 mg/kg BW were found to be normal. In addition, repeated doses of EC extract failed to influence any systematic parameters of treatment-related toxic symptoms such as food/water consumption, mortality, urinalysis, hematology, serum biochemistry, organ weight, or histopathology. These results indicated that the no-observed-adverse-effect level for the EC extract was 3000 mg/kg/day for male and female rats. Data obtained from Ames test, chromosome aberration assay, and micronucleus assay indicated that EC extract was not mutagenic or clastogenic. Taken together, these results support the safety of enzymatic EC extract as a potential therapeutic for human consumption against various diseases.HighlightsWe conducted acute, subchronic toxicity and genotoxicity studies of EC extract.In acute toxicity study, LD50 were higher than 3000 mg/kg in rats and beagle dogs.In subchronic study, NOAEL was determined to be greater than 3000 mg/kg/day in rats.In genotoxicity studies, EC extract was not clastogenic and mutagenic.

    loading  Loading Related Articles